📊 HAE Key Takeaways
Is HAE a Good Investment? Thesis Analysis
Haemonetics demonstrates excellent profitability with 59.7% gross margins and 11.9% net margins, coupled with exceptional free cash flow generation of $207.2M (21% FCF margin). The company maintains a strong financial position with $363.4M cash, manageable leverage (1.34x debt/equity), and solid interest coverage, providing a stable foundation. However, flat revenue growth is a material concern that limits confidence; the 44.5% EPS growth appears driven by operational leverage and share optimization rather than business expansion.
Haemonetics shows strong profitability and cash generation, with nearly 60% gross margin, 18% operating margin, and a robust 21% free cash flow margin supporting a moderate-leverage balance sheet. EPS growth outpaced flat revenue on margin expansion and cost discipline; sustaining efficiency while reaccelerating top-line growth is the swing factor. Solid liquidity and free cash flow provide room to delever and invest, warranting a constructive view despite growth stagnation.
Why Buy HAE? Key Strengths
- Industry-leading profitability metrics with 59.7% gross margin and 11.9% net margin
- Exceptional free cash flow generation of $207.2M with 21% FCF margin, demonstrating superior cash conversion
- Strong balance sheet with $363.4M cash, reasonable 1.34x debt/equity ratio, and 5.0x interest coverage ratio
- Efficient capital allocation with minimal capex ($15.1M) relative to operating cash flow
- Healthy liquidity ratios (1.75x current, 1.15x quick) providing financial flexibility
- High margins with strong FCF conversion (21% FCF margin)
- EPS up 44.5% YoY on operating leverage and cost control
- Adequate liquidity (1.75x current, 1.15x quick) supporting flexibility
HAE Investment Risks to Consider
- Zero revenue growth YoY signals stagnation or market headwinds in core business
- EPS growth driven by operational leverage and capital optimization rather than organic revenue expansion, which is unsustainable
- Elevated debt/equity ratio of 1.34x limits financial flexibility for strategic investments or downturns
- Low ROA of 4.7% indicates inefficient asset deployment relative to $2.5B asset base
- No insider trading activity in last 90 days may indicate limited management confidence or conviction in near-term outlook
- Flat revenue growth limits operating leverage and scale benefits
- Moderate-high leverage (Debt/Equity 1.34x) with only 5.0x interest coverage
- Profitability gains may be hard to sustain if mix/cost tailwinds fade
Key Metrics to Watch
- Revenue growth trajectory and return to positive YoY growth
- Operating cash flow sustainability as the company's primary strength
- Debt reduction strategy to optimize leverage ratios below 1.2x
- Gross margin preservation amid potential pricing pressures
- Capital allocation decisions (buybacks vs. debt paydown vs. strategic investments)
- Revenue growth (YoY)
- Interest coverage
HAE Financial Metrics
💡 AI Analyst Insight
The 21.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
HAE Profitability Ratios
HAE vs Healthcare Sector
How HAEMONETICS CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HAE Overvalued or Undervalued?
Based on fundamental analysis, HAEMONETICS CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HAE Balance Sheet & Liquidity
HAE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: HAEMONETICS CORP's revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $2.24 reflects profitable operations.
HAE Growth Metrics (YoY)
HAE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $339.0M | $33.8M | $0.74 |
| Q2 2026 | $327.3M | $33.8M | $0.66 |
| Q1 2026 | $321.4M | $34.0M | $0.70 |
| Q3 2025 | $336.3M | $24.9M | $0.61 |
| Q2 2025 | $318.2M | $24.9M | $0.48 |
| Q1 2025 | $311.3M | $38.4M | $0.74 |
| Q3 2024 | $305.3M | $19.9M | $0.61 |
| Q2 2024 | $297.5M | $19.9M | $0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HAE Capital Allocation
HAE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for HAEMONETICS CORP (CIK: 0000313143)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HAE
What is the AI rating for HAE?
HAEMONETICS CORP (HAE) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HAE's key strengths?
Claude: Industry-leading profitability metrics with 59.7% gross margin and 11.9% net margin. Exceptional free cash flow generation of $207.2M with 21% FCF margin, demonstrating superior cash conversion. ChatGPT: High margins with strong FCF conversion (21% FCF margin). EPS up 44.5% YoY on operating leverage and cost control.
What are the risks of investing in HAE?
Claude: Zero revenue growth YoY signals stagnation or market headwinds in core business. EPS growth driven by operational leverage and capital optimization rather than organic revenue expansion, which is unsustainable. ChatGPT: Flat revenue growth limits operating leverage and scale benefits. Moderate-high leverage (Debt/Equity 1.34x) with only 5.0x interest coverage.
What is HAE's revenue and growth?
HAEMONETICS CORP reported revenue of $987.7M.
Does HAE pay dividends?
HAEMONETICS CORP does not currently pay dividends.
Where can I find HAE SEC filings?
Official SEC filings for HAEMONETICS CORP (CIK: 0000313143) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HAE's EPS?
HAEMONETICS CORP has a diluted EPS of $2.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HAE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HAEMONETICS CORP has a BUY rating with 71% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HAE stock overvalued or undervalued?
Valuation metrics for HAE: ROE of 12.9% (sector avg: 15%), net margin of 11.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HAE stock in 2026?
Our dual AI analysis gives HAEMONETICS CORP a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HAE's free cash flow?
HAEMONETICS CORP's operating cash flow is $222.3M, with capital expenditures of $15.1M. FCF margin is 21.0%.
How does HAE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 11.9% (avg: 12%), ROE 12.9% (avg: 15%), current ratio 1.75 (avg: 2).